Termination

ALMAC - active and placebo capsule manufacture for the LAMDARCT Clinical Trial ​

  • Belfast Health & Social Care Trust

UK12: Procurement termination notice - Procurement Act 2023 - view information about notice types

Notice identifier: 2025/S 000-080707

Procurement identifier (OCID): ocds-h6vhtk-058571 (view related notices)

Published 8 December 2025, 3:19pm



Contract 1. Active and placebo capsule manufacture for the LAMDARCT Clinical Trial

This contract will not be signed.

Date of decision not to sign contract

5 December 2025

Reason for not signing contract

Start date, value and scope have changed, a UK5 and UK6 will be published for a new procurement.

Supplier

Contract value

  • £416,789.25 excluding VAT
  • £500,147.10 including VAT

Contract dates

  • 1 November 2025 to 1 November 2029
  • 4 years, 1 day

Supplier

ALMAC CLINICAL SERVICES LIMITED

  • Companies House: NI041905
  • Public Procurement Organisation Number: PRCD-2287-GMQG

Almac House

Craigavon

BT63 5QD

United Kingdom

Region: UKN07 - Armagh City, Banbridge and Craigavon

Small or medium-sized enterprise (SME): No

Voluntary, community or social enterprise (VCSE): No

Supported employment provider: No

Public service mutual: No

Contract 1. Active and placebo capsule manufacture for the LAMDARCT Clinical Trial


Contracting authority

Belfast Health & Social Care Trust

  • Public Procurement Organisation Number: PLQJ-5727-JCLR

Trust Headquarters, 2nd Floor, Non Clinical Support Building, Royal Victoria Hospital

Belfast

BT12 6BA

United Kingdom

Region: UKN06 - Belfast

Organisation type: Public authority - central government

Devolved regulations that apply: Northern Ireland